JP2019517541A5 - - Google Patents

Download PDF

Info

Publication number
JP2019517541A5
JP2019517541A5 JP2018563831A JP2018563831A JP2019517541A5 JP 2019517541 A5 JP2019517541 A5 JP 2019517541A5 JP 2018563831 A JP2018563831 A JP 2018563831A JP 2018563831 A JP2018563831 A JP 2018563831A JP 2019517541 A5 JP2019517541 A5 JP 2019517541A5
Authority
JP
Japan
Prior art keywords
composition according
composition
stabilizer
microns
cysteamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018563831A
Other languages
English (en)
Japanese (ja)
Other versions
JP7195934B2 (ja
JP2019517541A (ja
Filing date
Publication date
Priority claimed from GBGB1609940.0A external-priority patent/GB201609940D0/en
Application filed filed Critical
Publication of JP2019517541A publication Critical patent/JP2019517541A/ja
Publication of JP2019517541A5 publication Critical patent/JP2019517541A5/ja
Application granted granted Critical
Publication of JP7195934B2 publication Critical patent/JP7195934B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018563831A 2016-06-07 2017-06-06 硫黄含有化合物を含む微小粒子 Active JP7195934B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346969P 2016-06-07 2016-06-07
US62/346,969 2016-06-07
GBGB1609940.0A GB201609940D0 (en) 2016-06-07 2016-06-07 Microparticles
GB1609940.0 2016-06-07
PCT/GB2017/051637 WO2017212249A1 (en) 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound

Publications (3)

Publication Number Publication Date
JP2019517541A JP2019517541A (ja) 2019-06-24
JP2019517541A5 true JP2019517541A5 (cg-RX-API-DMAC7.html) 2020-07-09
JP7195934B2 JP7195934B2 (ja) 2022-12-26

Family

ID=56508202

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018563831A Active JP7195934B2 (ja) 2016-06-07 2017-06-06 硫黄含有化合物を含む微小粒子

Country Status (16)

Country Link
US (1) US11369568B2 (cg-RX-API-DMAC7.html)
EP (1) EP3463325B1 (cg-RX-API-DMAC7.html)
JP (1) JP7195934B2 (cg-RX-API-DMAC7.html)
KR (1) KR102412212B1 (cg-RX-API-DMAC7.html)
CN (1) CN109310654A (cg-RX-API-DMAC7.html)
AU (1) AU2017277897B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018075221B1 (cg-RX-API-DMAC7.html)
CA (2) CA3096121C (cg-RX-API-DMAC7.html)
DK (1) DK3463325T3 (cg-RX-API-DMAC7.html)
ES (1) ES2965017T3 (cg-RX-API-DMAC7.html)
FI (1) FI3463325T3 (cg-RX-API-DMAC7.html)
GB (1) GB201609940D0 (cg-RX-API-DMAC7.html)
MX (1) MX2018014278A (cg-RX-API-DMAC7.html)
SG (1) SG11201810934TA (cg-RX-API-DMAC7.html)
WO (1) WO2017212249A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201807852B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
EP3572068A1 (en) * 2018-05-22 2019-11-27 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. New salt of cysteamine for the preparation of highly respirable particles
WO2020079186A1 (en) * 2018-10-17 2020-04-23 Novabiotics Limited Dosage regime
KR20230061365A (ko) * 2020-09-03 2023-05-08 필립모리스 프로덕츠 에스.에이. 분무 건조 저 흡습성 활성 분말 조성물
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023107996A1 (en) * 2021-12-07 2023-06-15 Cila Therapeutic Inc. Anti-viral therapeutic agents and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8901570D0 (sv) * 1989-05-02 1989-05-02 Draco Ab Organic salts of cysteine derivatives
KR100770362B1 (ko) * 2004-12-30 2007-10-26 (주)두비엘 분무건조 고분자형 콜렉틴족 단백질 및 그의 제조방법
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
KR101433152B1 (ko) 2006-12-22 2014-08-22 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 안과용 약물의 전달에 유용한 젤
CN101342155B (zh) * 2007-07-11 2012-01-04 天津帝士力投资控股集团有限公司 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法
CA2744655A1 (en) * 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh Novel powdered crystalline medicines for inhalation
EP2393491B1 (en) * 2009-02-03 2020-04-22 Microbion Corporation Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
WO2010138419A2 (en) 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Materials and methods for treating viral infections
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
BR112013029803B1 (pt) 2011-05-19 2021-07-13 Savara, Inc Composições de vancomicina em pó seco
JP5981123B2 (ja) * 2011-10-11 2016-08-31 サンサ コーポレーション (バルバドス) インク ニコチン薬の製造法およびその方法により製造される医薬
CA2853484C (en) * 2011-10-26 2018-08-21 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
EP2811991A4 (en) 2012-02-10 2016-03-16 Whitehead Biomedical Inst INHIBITION OF THE GLYCIN CLEAVAGE SYSTEM FOR THE TREATMENT OF CANCER
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
US9925184B2 (en) * 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
GB201416716D0 (en) 2014-09-22 2014-11-05 Novabiotics Ltd Use
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
US10905660B2 (en) * 2016-06-07 2021-02-02 Novabiotics Limited Microparticles

Similar Documents

Publication Publication Date Title
JP2019517541A5 (cg-RX-API-DMAC7.html)
HRP20211035T1 (hr) Tekuća formulacija za inhalaciju koja sadrži rpl554
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
JP2015509788A5 (cg-RX-API-DMAC7.html)
JP2007505830A5 (cg-RX-API-DMAC7.html)
FI3463325T3 (fi) Mikrohiukkaset, jotka käsittävät rikkiä sisältävää yhdistettä
JP2016534153A5 (cg-RX-API-DMAC7.html)
HRP20210749T1 (hr) Farmaceutski pripravci koji sadrže azd9291
HRP20130052T1 (hr) Lijeäśenje respiratorne bolesti
JP2013536845A5 (cg-RX-API-DMAC7.html)
HRP20220919T3 (hr) Sastav za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne bolesti pluća
JP2012176990A5 (cg-RX-API-DMAC7.html)
IL273388B2 (en) Preparations and methods for treating and improving respiratory conditions and mucosal inflammation
JP2016512494A5 (cg-RX-API-DMAC7.html)
JP2011520911A5 (cg-RX-API-DMAC7.html)
JP2012503668A5 (cg-RX-API-DMAC7.html)
SI2760821T1 (en) A salt salt of an anti-inflammatory substituted cyclobutenedione compound
JP2017528479A5 (cg-RX-API-DMAC7.html)
JP2016513625A5 (cg-RX-API-DMAC7.html)
JP2020513032A5 (cg-RX-API-DMAC7.html)
CO6361899A2 (es) Pariculas inhalables que comprenden tiotropio
JP2015510916A5 (cg-RX-API-DMAC7.html)
JP2008518007A5 (cg-RX-API-DMAC7.html)
JP2018537453A5 (cg-RX-API-DMAC7.html)
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.